![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » AMGEN GETS PRIORITY REVIEW FROM FDA, PLANS TO TRIPLE STAFF IN JAPAN TO SELL ITS OWN DRUGS
AMGEN GETS PRIORITY REVIEW FROM FDA, PLANS TO TRIPLE STAFF IN JAPAN TO SELL ITS OWN DRUGS
June 13, 2006
Amgen Inc. said that Food and Drug Administration has granted priority review of its panitumumab treatment for patients with metastatic colorectal cancer in an announcement Monday after the market closed, and also announced Tuesday that it will triple the number of its employees in Japan by 2010 to begin selling its new cancer drugs on its own. Los Angeles Business (http://losangeles.bizjournals.com/losangeles/stories/2006/06/12/daily18.html)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct